NAFAZAIR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).

How it works

Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.

What the body does with it

Metabolism	Not metabolized; acts locally with negligible systemic absorption.
Excretion	Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Half-life	Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Protein binding	92-96% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8-1.2 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral: 70-85% due to moderate first-pass metabolism.
Onset of Action	Intravenous: 5-10 minutes; Oral: 30-60 minutes.
Duration of Action	4-6 hours for clinical effect; may be prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

2.5 mg subcutaneously once daily.

Dosage form	SOLUTION/DROPS
Renal impairment	No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min (including dialysis), avoid use.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 1.25 mg subcutaneously once daily; Child-Pugh C: avoid use.
Pediatric use	Not approved for use in pediatric patients (safety and efficacy not established).
Geriatric use	No specific adjustment required; monitor renal function closely due to age-related decline.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).

Breastfeeding	No data on excretion in human milk; M/P ratio unknown. Caution advised; consider risks and benefits.
Teratogenic Risk	No human data available; animal studies not conducted. Use only if benefit outweighs risk. First trimester: insufficient evidence of teratogenicity. Second/third trimester: no known fetal adverse effects.
Fetal Monitoring	Monitor maternal vital signs and fetal heart rate during administration.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component of the product"]

Clinical Precautions

Precautions

["For intravaginal use only","May weaken latex condoms and diaphragms","Discontinue if hypersensitivity occurs"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NAFAZAIR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).

How it works

Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.

What the body does with it

Metabolism	Not metabolized; acts locally with negligible systemic absorption.
Excretion	Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Half-life	Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Protein binding	92-96% bound to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8-1.2 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral: 70-85% due to moderate first-pass metabolism.
Onset of Action	Intravenous: 5-10 minutes; Oral: 30-60 minutes.
Duration of Action	4-6 hours for clinical effect; may be prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

2.5 mg subcutaneously once daily.

Dosage form	SOLUTION/DROPS
Renal impairment	No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min (including dialysis), avoid use.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 1.25 mg subcutaneously once daily; Child-Pugh C: avoid use.
Pediatric use	Not approved for use in pediatric patients (safety and efficacy not established).
Geriatric use	No specific adjustment required; monitor renal function closely due to age-related decline.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).

Breastfeeding	No data on excretion in human milk; M/P ratio unknown. Caution advised; consider risks and benefits.
Teratogenic Risk	No human data available; animal studies not conducted. Use only if benefit outweighs risk. First trimester: insufficient evidence of teratogenicity. Second/third trimester: no known fetal adverse effects.
Fetal Monitoring	Monitor maternal vital signs and fetal heart rate during administration.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component of the product"]

Clinical Precautions

Precautions

["For intravaginal use only","May weaken latex condoms and diaphragms","Discontinue if hypersensitivity occurs"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…